Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
FLAGYL I.V. vs ARESTOCAINE HYDROCHLORIDE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Metronidazole, a nitroimidazole antibiotic, is reduced by bacterial nitroreductases to form reactive intermediates that disrupt bacterial DNA and inhibit nucleic acid synthesis.
Arestocaine hydrochloride is a local anesthetic of the amide type. It stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses, thereby effecting local anesthesia.
Intra-abdominal infections (e.g., peritonitis, abscess),Pelvic inflammatory disease,Bacterial vaginosis,Surgical prophylaxis,Anaerobic infections (e.g., Clostridium, Bacteroides),Off-label: Helicobacter pylori eradication, rosacea, Crohn's disease
Local or regional anesthesia for dental procedures,Infiltration anesthesia,Nerve block anesthesia
500 mg IV every 6 hours. For severe infection, 750 mg IV every 6 hours.
2-5 mg/kg intramuscularly every 60-90 minutes, not to exceed 500 mg total dose in a 12-hour period.
8 hours (range 6-12 hours) in adults; prolonged in hepatic impairment (up to 20 hours) and neonates.
Terminal elimination half-life is approximately 1.5–2 hours in adults with normal hepatic and renal function; prolonged in hepatic impairment or congestive heart failure.
Hepatic metabolism via oxidation and glucuronidation; major metabolites: hydroxy metabolite (active) and acetic acid metabolite; CYP450 involvement primarily CYP2A6 and CYP3A4.
Primarily metabolized by the liver via hydrolysis by esterases (though it is an amide, it may be partially hydrolyzed) and conjugation. The major metabolic pathways involve CYP1A2 and CYP3A4.
Renal (60-80% unchanged), fecal (6-15% as metabolites), biliary (minor).
Renal excretion of unchanged drug and metabolites; approximately 90% excreted in urine as parent compound and metabolites (60% as unchanged drug, 30% as metabolites), with less than 10% fecal elimination.
Less than 20%, primarily bound to albumin.
Approximately 70% bound primarily to alpha-1-acid glycoprotein (AAG) and to a lesser extent albumin.
0.5-0.8 L/kg; indicates extensive tissue distribution, including CNS, bone, and abscesses.
Volume of distribution is 0.8–1.5 L/kg, reflecting extensive tissue distribution; higher in neonates and infants.
Intravenous: 100%.
Topical: variable, approximately 30–50% absorbed through intact skin; Oral: negligible due to extensive first-pass metabolism (bioavailability <10%); Intravenous: 100%.
No dose adjustment for Cr Cl >10 m L/min. For Cr Cl <10 m L/min, extend interval to every 12 hours. For hemodialysis, administer dose post-dialysis.
GFR 30-50 m L/min: reduce dose by 25%; GFR 15-29 m L/min: reduce dose by 50%; GFR <15 m L/min: avoid use.
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose by 50%. Child-Pugh C: reduce dose by 75%.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use.
Loading dose: 15 mg/kg IV. Maintenance: 7.5 mg/kg IV every 6 hours. Maximum single dose: 750 mg.
1-3 mg/kg intramuscularly every 60-90 minutes, max 200 mg per dose; maximum cumulative dose 400 mg/12 hours.
Monitor renal function; adjust dose based on Cr Cl. No specific age-related dose reduction.
Initiate at lowest effective dose (2 mg/kg) due to increased sensitivity and potential for prolonged duration; monitor for adverse effects.
Carcinogenicity has been observed in chronic animal studies; avoid chronic use unless necessary.
There is no FDA black box warning for Arestocaine hydrochloride.
Peripheral neuropathy and central nervous system toxicity (e.g., seizures, encephalopathy) with prolonged use; discontinue if neurological symptoms appear; use with caution in hepatic impairment; may cause disulfiram-like reaction with alcohol.
Risk of systemic toxicity if injected intravascularly,Use with caution in patients with hepatic impairment,Use with caution in patients with cardiovascular disease,Risk of methemoglobinemia in patients with glucose-6-phosphate dehydrogenase deficiency
Hypersensitivity to metronidazole or nitroimidazoles; first trimester of pregnancy; concomitant use with disulfiram or alcohol.
Hypersensitivity to amide-type local anesthetics,Severe hypotension,Myasthenia gravis (relative contraindication),Bradycardia
Avoid alcohol and any products containing ethanol (e.g., cough syrups, mouthwash) during therapy and for at least 48 hours after completion. No specific food restrictions.
No specific food interactions; avoid hot foods until numbness resolves to prevent burns.
Flagyl I. V. (metronidazole) crosses the placenta. First trimester: Avoid unless essential; no clear evidence of major malformations but risk cannot be excluded (FDA category B). Second and third trimesters: Use only if clearly needed; no documented fetal toxicity at usual doses.
Pregnancy Category C. Animal reproduction studies have not been conducted. In first trimester, limited data; potential for adverse effects on fetal development cannot be excluded. In second and third trimesters, risk of placental transfer and fetal bradycardia; use only if clearly needed.
Metronidazole is excreted in breast milk; M/P ratio approximately 0.9-1.0. Peak milk concentration 2-4 hours after dose. Breastfeeding not recommended during therapy and for 24 hours after the last dose due to potential carcinogenicity and adverse effects in infant.
No data on excretion in human milk. M/P ratio unknown. Caution advised; discontinue breastfeeding or drug based on importance of drug to mother.
No specific dose adjustments required in pregnancy. Pharmacokinetic changes (increased volume of distribution, renal clearance) may slightly reduce serum levels but not necessitate dose modification. Use standard adult dosing with caution in severe hepatic impairment.
Increased plasma volume and decreased plasma protein binding may require dose adjustments. However, no established guidelines; use lowest effective dose and shortest duration.
FLAGYL I. V. (metronidazole) is a nitroimidazole antibiotic with potent anaerobic coverage. It is the drug of choice for Clostridioides difficile infection, but oral vancomycin is preferred for severe cases. IV formulation is used when oral route is not feasible. Monitor for peripheral neuropathy with prolonged use. Avoid alcohol during therapy and for 48 hours after last dose due to disulfiram-like reaction. Dose adjustment required in severe hepatic impairment (Child-Pugh C). Metronidazole can prolong QT interval; use caution with other QT-prolonging drugs. It is compatible with most IV solutions but avoid mixing with calcium-containing solutions.
ARESTOCAINE HYDROCHLORIDE (presumed anesthetic) is not a recognized drug; likely a misspelling of articaine or similar. If referring to articaine, clinical pearls: 1) Onset within 1-3 minutes, duration 1-3 hours; 2) Metabolized by plasma esterases, caution in pseudocholinesterase deficiency; 3) Maximum dose 7 mg/kg (adults) to avoid CNS/cardiac toxicity; 4) Contains sulfites, avoid in allergic patients.
Avoid alcohol and alcohol-containing products during treatment and for 48 hours after the last dose to prevent severe nausea, vomiting, headache, and flushing.,Inform your doctor if you experience numbness or tingling in your hands or feet, as this may indicate nerve damage.,Report any new or worsening symptoms, especially if you have liver disease or are on blood thinners like warfarin (metronidazole can increase INR).,Do not take this medication if you are pregnant without consulting your doctor, especially in the first trimester.,Shake the IV bag gently before use; do not use if the solution is cloudy or contains particles.
Avoid chewing or biting lips/cheeks while numb to prevent injury.,Report any signs of allergic reaction (rash, swelling, difficulty breathing) immediately.,Do not consume hot foods or beverages until sensation returns.,Inform dentist of all medications, especially MAOIs or anticoagulants.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about FLAGYL I.V. vs ARESTOCAINE HYDROCHLORIDE, answered by our medical review team.
FLAGYL I.V. is a Nitroimidazole Antibiotic that works by Metronidazole, a nitroimidazole antibiotic, is reduced by bacterial nitroreductases to form reactive intermediates that disrupt bacterial DNA and inhibit nucleic acid synthesis.. ARESTOCAINE HYDROCHLORIDE is a Local Anesthetic that works by Arestocaine hydrochloride is a local anesthetic of the amide type. It stabilizes the neuronal membrane by inhibiting the ionic fluxes required for the initiation and conduction of impulses, thereby effecting local anesthesia.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between FLAGYL I.V. and ARESTOCAINE HYDROCHLORIDE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of FLAGYL I.V. is: 500 mg IV every 6 hours. For severe infection, 750 mg IV every 6 hours.. The standard adult dose of ARESTOCAINE HYDROCHLORIDE is: 2-5 mg/kg intramuscularly every 60-90 minutes, not to exceed 500 mg total dose in a 12-hour period.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between FLAGYL I.V. and ARESTOCAINE HYDROCHLORIDE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. FLAGYL I.V. is classified as Category C. Flagyl I.V. (metronidazole) crosses the placenta. First trimester: Avoid unless essential; no clear evidence of major malformations but risk cannot be excluded (FDA category B). Se. ARESTOCAINE HYDROCHLORIDE is classified as Category C. Pregnancy Category C. Animal reproduction studies have not been conducted. In first trimester, limited data; potential for adverse effects on fetal development cannot be excluded. . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.